秋水仙碱及利伐沙班联合阿司匹林对住院COVID-19患者的疗效:ACT开放标签析因随机对照试验
ACT住院试验在11国62中心纳入2749例住院COVID-19患者,2×2析因设计评估秋水仙碱及利伐沙班联合阿司匹林。
要点
- 秋水仙碱不降低住院COVID-19患者疾病进展或死亡风险。
- 利伐沙班联合阿司匹林不降低主要血栓复合结局风险。
核心结论
- 在住院COVID-19患者中,秋水仙碱及利伐沙班联合阿司匹林均不能预防疾病进展或死亡。
研究设计与样本
- ACT住院试验为开放标签、2×2析因、随机对照试验,在11国62中心进行。
- 纳入≥18岁症状性、实验室确诊COVID-19且住院72小时内或住院后临床恶化患者。
- 2749例随机,秋水仙碱分析2611例(秋水仙碱1304例 vs 对照1307例),联合抗栓分析2119例(联合组1063例 vs 对照1056例)。
- 主要结局在45天意向性治疗人群评估;秋水仙碱主要结局为需高流量氧疗、机械通气或死亡复合终点;联合抗栓主要结局为主要血栓(心梗、卒中、急性肢体缺血或肺栓塞)、需高流量氧疗、机械通气或死亡复合终点。
主要发现
- 亚组(疫苗接种状态、基线疾病严重程度、随机化距症状发作时间)结果一致。
临床怎么用
- 不推荐对住院COVID-19患者常规使用秋水仙碱以预防疾病进展。
- 不推荐对住院COVID-19患者常规使用利伐沙班联合阿司匹林以预防血栓或疾病进展。
- 若考虑联合抗栓治疗,需权衡出血风险增加。
局限性
- 开放标签设计,研究者和患者未设盲。
- 试验仍在进行中(注册号NCT04324463)。
- 联合抗栓分析样本量(2119例)少于秋水仙碱分析(2611例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: COVID-19 disease is accompanied by a dysregulated immune response and hypercoagulability. The Anti-Coronavirus Therapies (ACT) inpatient trial aimed to evaluate anti-inflammatory therapy with colchicine and antithrombotic therapy with the combination of rivaroxaban and aspirin for prevention of disease progression in patients hospitalised with COVID-19. METHODS: The ACT inpatient, open-label, 2 × 2 factorial, randomised, controlled trial was done at 62 clinical centres in 11 countries. Patients aged at least 18 years with symptomatic, laboratory confirmed COVID-19 who were within 72 h of hospitalisation or worsening clinically if already hospitalised were randomly assigned (1:1) to receive colchicine 1·2 mg followed by 0·6 mg 2 h later and then 0·6 mg twice daily for 28 days versus usual care; and in a second (1:1) randomisation, to the combination of rivaroxaban 2·5 mg twice daily plus aspirin 100 mg once daily for 28 days versus usual care. Investigators and patients were not masked to treatment allocation. The primary outcome, assessed at 45 days in the intention-to-treat population, for the colchicine randomisation was the composite of the need for high-flow oxygen, mechanical ventilation, or death; and for the rivaroxaban plus aspirin randomisation was the composite of major thrombosis (myocardial infarction, stroke, acute limb ischaemia, or pulmonary embolism), the need for high-flow oxygen, mechanical ventilation, or death. The trial is registered at www. CLINICALTRIALS: gov, NCT04324463 and is ongoing. FINDINGS: Between Oct 2, 2020, and Feb 10, 2022, at 62 sites in 11 countries, 2749 patients were randomly assigned to colchicine or control and the combination of rivaroxaban and aspirin or to the control. 2611 patients were included in the analysis of colchicine (n=1304) versus control (n=1307); 2119 patients were included in the analysis of rivaroxaban and aspirin (n=1063) versus control (n=1056). Follow-up was more than 98% complete. Overall, 368 (28·2%) of 1304 patients allocated to colchicine and 356 (27·2%) of 1307 allocated to control had a primary outcome (hazard ratio [HR] 1·04, 95% CI 0·90-1·21, p=0·58); and 281 (26·4%) of 1063 patients allocated to the combination of rivaroxaban and aspirin and 300 (28·4%) of 1056 allocated to control had a primary outcome (HR 0·92, 95% CI 0·78-1·09, p=0·32). Results were consistent in subgroups defined by vaccination status, disease severity at baseline, and timing of randomisation in relation to onset of symptoms. There was no increase in the number of patients who had at least one serious adverse event for colchicine versus control groups (87 [6·7%] of 1304 vs 90 [6·9%] of 1307) or with rivaroxaban and aspirin versus control groups (85 [8·0%] vs 91 [8·6%]). Among patients assigned to colchicine, 8 (0·61%) had adverse events that led to discontinuation of study drug, mostly gastrointestinal in nature. 17 (1·6%) patients assigned to the combination of rivaroxaban and aspirin had bleeding compared with seven (0·66%) of those allocated to control (p=0·042); the number of serious bleeding events was two (0·19%) versus six (0·57%), respectively (p=0·18). No patients assigned to rivaroxaban and aspirin had serious adverse events that led to discontinuation of study drug. INTERPRETATION: Among patients hospitalised with COVID-19, neither colchicine nor the combination of rivaroxaban and aspirin prevent disease progression or death. FUNDING: Canadian Institutes for Health Research, Bayer, Population Health Research Institute, Hamilton Health Sciences Research Institute, Thistledown Foundation. TRANSLATIONS: For the Portuguese, Russian and Spanish translations of the abstract see Supplementary Materials section.
引用
- Eikelboom JW, Jolly SS, Belley-Cote EP, et al. Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial. Lancet Respir Med. 2022. PMID: 36228641. doi:10.1016/S2213-2600(22)00298-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。